ITEOS THERAPEUTICS INC. - COMMON STOCK

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

28 Apr 2025 16:30:00 By Nasdaq GlobeNewswire

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

25 Mar 2025 16:35:00 By Nasdaq GlobeNewswire

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

05 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

10 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

08 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

12 Dec 2024 08:55:00 By Nasdaq GlobeNewswire

iTeos to Participate in Upcoming Investor Conferences

26 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

12 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

24 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

14 Sep 2024 02:30:00 By Nasdaq GlobeNewswire

iTeos to Participate in Upcoming Investor Conferences

28 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

20 Aug 2024 08:30:55 By Nasdaq GlobeNewswire

iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates

08 Aug 2024 07:00:01 By Nasdaq GlobeNewswire

iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

05 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

08 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

17 Jun 2024 09:00:00 By Nasdaq GlobeNewswire

iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

10 May 2024 08:26:01 By Nasdaq GlobeNewswire

iTeos Therapeutics Announces $120 Million Registered Direct Offering

10 May 2024 08:24:05 By Nasdaq GlobeNewswire

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

07 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

06 Mar 2024 07:01:00 By Nasdaq GlobeNewswire